AIM ImmunoTech Inc.
New York Stock Exchange AmericanCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Thomas K. Equels
- Full Time Employees
- 21
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 2117 SW Highway 484 Ocala FL United States of America 34473
- IPO Date
- Nov 2, 1995
- CIK
- 0000946644
- Website
- aimimmuno.com
- Similar Companies
- Business
- AIM ImmunoTech Inc. is a leading immuno-pharmaceutical company dedicated to the research and development of innovative therapies for a variety of cancers, viral infections, and immune system disorders. The company's flagship investigational drug, Ampligen (rintatolimod), is a synthetic double-stranded RNA molecule operating as a Toll-like Receptor 3 (TLR3) agonist. Ampligen is being explored in multiple clinical trials for various solid tumor cancers, including a primary focus on metastatic pancreatic cancer, where it is being evaluated in combination with other immunotherapies. It is also undergoing assessment for applications in conditions such as myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and post-COVID conditions, with positive preliminary data reported in these areas. Ampligen is commercially approved in Argentina for treating severe chronic fatigue syndrome. Beyond Ampligen, the company offers Alferon N Injection, a natural alpha interferon formulation approved for treating refractory genital warts. AIM ImmunoTech actively engages in strategic collaborations with major cancer research centers and has secured patents for Ampligen's use in combination therapies for various cancers and for long-COVID treatments in key markets like Japan and Europe. Headquartered in Ocala, Florida, the company, formerly known as Hemispherx Biopharma, Inc., rebranded to AIM ImmunoTech Inc. in 2019, reflecting its core mission in amplified immunological modulation. The company continues to advance its pipeline with an emphasis on addressing unmet medical needs in oncology and debilitating chronic conditions.
AIM ImmunoTech Completes Phase 2 DURIPANC Enrollment Milestone Ahead of Schedule, Advancing Ampligen Toward Critical Pancreatic Cancer Clinical Milestones
AIM ImmunoTech Announces Emerging Ebola Opportunity for Ampligen Amid Escalating Global Health Concerns and WHO Emergency Declaration
Creo Medical Group to raise £5.5m and advance partial divestment
AIM ImmunoTech Announces $2.4 Million Financing, Including Concurrent Registered Direct Offering and Private Placement
AIM ImmunoTech Announces $2.4 Million Financing, Including Concurrent Registered Direct Offering and Private Placement
88 Energy says Augusta-1 exploration well is on track for Q1 2027
CMMI Institute Completes Pilot for New AI Maturity (AIM) Framework
AIM ImmunoTech Announces Significant Increase in Stockholder Equity and Extension of Promissory Note Maturity Date to June 2027, Enhancing Financial Flexibility and Supporting Strategic Clinical Priorities
Europa Oil & Gas drops as North Yorkshire refuses planning for potential gas drilling
Sintana Energy raises $11.5m to support exploration plans in Namibia
CelLBxHealth strikes US clinical collaboration with AdventHealth cancer studies
Union Jack Oil says Crossroads well drilled on-budget, production testing due to start in June
AIM ImmunoTech Posts Virtual Investor Key Opinion Leader Segment Spotlighting Ampligen Breakthrough Data in Pancreatic Cancer
OptiBiotix shares surge 13.5% as company plans SweetBiotix showcase for investors
Aimia Inc. (AIM:CA) Shareholder/Analyst Call Transcript
Candor Technology Integrates with Freddie Mac's AIM Check API to Automate Income Calculations
Aimia Inc. (AIM:CA) Q1 2026 Earnings Call Transcript
Jersey Oil and Gas well placed to unlock value - broker
Bullish broker tips 88 Energy for substantial upside
88 Energy amends Namibia venture agreement as it focusses on Alaska